// App-Quantinova.ai

2981 : Pharmacokinetic and Pharmacodynamic Correlates from the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Researchers

Presenter

  • Joseph Boni

Principal Investigators

  • Karin Havenith

  • Mehdi Hamadani

  • Paolo F Caimi

  • Katie Anderson

  • Tim Kopotsha

  • Hans G Cruz

  • Jens Wuerthner

Medical Centers

  • Clinical Development, ADC Therapeutics, Murray Hill, NJ

  • Clinical Research, ADC Therapeutics (UK) Ltd, London, United Kingdom

  • Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

  • University Hospital of Cleveland, Cleveland, OH

  • Clinical Development, ADC Therapeutics, Epalinges, Switzerland

Locations

  • United States

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

Biomarkers

  • Natural Killer cells

  • Cluster of Differentiation 25

  • Cluster of Differentiation 2AP

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

Drug/Treatment

  • ADCT301

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Single Arm

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT04052997

Sponsors

  • ADC Therapeutics

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved